【摘要】 为了观察肺癌表皮生长因子受体-酪氨酸激酶抑制剂(EGFR-TKI)治疗失败后化疗与化疗联合EGFR-TKI的疗效,对46例晚期非小细胞肺癌患者EGFR-TKI治疗失败后,分别给予吉西他滨化疗、吉西他滨联合EGFR-TKI治疗。结果显示:两组在疾病控制率、无进展生存期及总生存期上均无统计学差异。吉西他滨联合EGFR-TKI组的不良反应发生率明显高于吉西他滨组(P<0.05)。因此对于肺癌EGFR-TKI治疗失败后,进行吉西他滨化疗与吉西他滨联合EGFRTKI治疗效果上未见差异,在毒副反应方面,吉西他滨化疗要优于吉西他滨联合EGFR-TKI治疗。更多还原

【Abstract】 To observe the effect of chemotherapy and chemotherapy combined EGFR-TKI in lung cancer after epidermal growth factor receptor-tyrosine kinase inhibitor(EGFR-TKI)treatment failure,46 patients with advanced non-small cell lung cancer were treated with gemcitabine or gemcitabine combined with EGFR-TKI therapy after EGFR-TKI treatment failure.The results showed that there was no significant difference between the two groups in the disease control rate,progression free survival and overall survival.The incidence of adverse reactions,gemcitabine combined with EGFR-TKI therapy group was significantly higher than gemcitabine group(P<0.05).Therefore,after the failure of EGFR-TKI treatment for lung cancer,there is no difference in the efficacy between gemcitabine and gemcitabine combined EGFR-TKI,and gemcitabine chemotherapy has less side effect than gemcitabine combined with EGFR-TKI therapy.更多还原